Nicholas Brodszki
1 – 10 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
First year of TREC-based national SCID screening in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence
(
- Contribution to journal › Article
-
Mark
Add-on or alone? Inhaled nebulized immunoglobulin reduces upper airway infections : 24 months of real-life experience
(
- Contribution to journal › Article
-
Mark
European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline : Deficiencies, Diagnosis, and Management
2020) In Journal of Clinical Immunology(
- Contribution to journal › Article
- 2019
-
Mark
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies
(
- Contribution to journal › Article
-
Mark
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents
(
- Contribution to journal › Article
- 2018
-
Mark
Kappa-deleting recombination excision circle levels remain low or undetectable throughout life in patients with X-linked agammaglobulinemia
(
- Contribution to journal › Article
- 2017
-
Mark
Screening protocols to monitor respiratory status in primary immunodeficiency disease : findings from a European survey and subclinical infection working group
(
- Contribution to journal › Article
-
Mark
Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.217-217(
- Contribution to journal › Published meeting abstract
-
Mark
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.216-216(
- Contribution to journal › Published meeting abstract